Abstract
Twenty-three children with first on-treatment marrow relapse of lymphoblastic leukaemia (ALL) were randomly assigned to treatment with vincristine (16 patients) or vindesine (7 patients) in an otherwise identical regimen including daunorubicin, prednisolone, asparaginase, VM26 and cytosine. There was no suggestion of any difference between the two groups in terms of frequency of secbnd remission achievement or duration, nor was there in terms of toxicity. Despite small numbers, these findings suggest that vindesine does not offer any obvious therapeutic advantage over vincristine in relapsed ALL, but is well tolerated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
